xCures is an AI-powered healthcare data platform that aggregates medical records from any U.S. care site, extracts and structures clinical, genomic, and imaging data into searchable, standardized FHIR records, delivering decision-ready insights within 15 minutes.[1][2][6] Originally focused on oncology since its 2018 founding, it now supports all therapeutic areas via SaaS and API integrations, serving healthcare providers, researchers, and organizations by solving the problem of fragmented, unstructured data that hinders clinical decisions, research, and workflows.[1][3][7] It transforms raw records—even faxes—into interoperable, verifiable data, reducing administrative burdens and enabling real-time, patient-centric longitudinal views for improved patient outcomes and innovation.[2][5]
The platform targets providers needing comprehensive patient histories, research organizations accelerating trials, and payers streamlining billing, with features like proprietary search algorithms doubling document retrieval and HITRUST-certified security ensuring compliance.[1][2][3]
Founded in 2018 and headquartered in Oakland, California, xCures emerged from a mission to tackle oncology's data challenges by assembling a team of experts in healthcare, AI, and oncology to extract insights from complex medical records.[1][4][6][8] The idea stemmed from the exploding volume of healthcare data and the difficulty in accessing relevant information, starting with an oncology focus to create structured, longitudinal patient profiles.[1][8]
Early traction came from real-world validation in oncology workflows, evolving to condition-agnostic capabilities with expansions like fax-to-FHIR automation and QHIN integration, positioning it as a trusted partner for clinical and research use.[1][2][7] CEO Mika Newton has emphasized its role in harnessing real-time, regulatory-grade data to drive care and innovation.[3]
xCures rides the wave of AI-driven healthcare interoperability amid exploding data volumes and regulatory pushes like TEFCA/QHIN, where fragmented records (80% unstructured) impede care and research.[1][2] Its timing aligns with post-pandemic demands for real-time insights, FHIR standardization, and real-world evidence (RWE) for drug development, filling gaps left by legacy systems reliant on faxes.[2][6]
Market forces favoring it include AI adoption in healthtech (projected $188B by 2030), value-based care needing longitudinal data, and research acceleration via de-identified datasets.[3][5][7] xCures influences the ecosystem by enabling secondary RWE datasets, boosting clinical trials, and embedding into workflows, democratizing U.S. healthcare data for innovation across specialties.[1][3]
xCures is poised for expansion as SaaS adoption grows, with potential to dominate RWE and AI analytics amid rising demand for multimodal data (clinical + genomic).[6][7] Trends like federated learning, edge AI for privacy, and global interoperability will shape it, possibly through partnerships with EHR giants or pharma for trial matching.
Its evolution from oncology niche to full-spectrum platform signals scalable impact, likely amplifying influence in precision medicine—turning data chaos into the fuel for next-gen healthcare breakthroughs, much like its core promise of clarity from complexity.[1][3]
xCures has raised $130K in total across 1 funding round.
xCures's investors include Acrew Capital, at.inc/, Blank Ventures, Fuel Capital, Montage Ventures, MS&AD Ventures, SV Angel, Ulu Ventures, Antoine Nivard, Leah Busque, Oshri Kaplan.
xCures has raised $130K across 1 funding round. Most recently, it raised $130K Series A in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $130K Series A | Acrew Capital, at.inc/, Blank Ventures, Fuel Capital, Montage Ventures, MS&AD Ventures, SV Angel, Ulu Ventures, Antoine Nivard, Leah Busque, Oshri Kaplan |
